Lindo Tube
Lindo Tube – prevent infection during ventilation
Reduce infection risk during ventilation without disrupting clinical workflow.
Lindo Tube is a first-in-class antimicrobial blue light (aBL) endotracheal tube designed to deliver continuous antimicrobial protection inside the airway. Developed to target bacterial contamination at the source, Lindo Tube supports a new model of infection prevention in critical care environments.
Healthcare-associated infections including ventilator-associated pneumonia (VAP) remain one of the most significant and costly challenges in intensive care globally. Current prevention strategies rely heavily on antibiotics, manual intervention and fragmented infection control processes. Lindo Tube is designed to help shift healthcare from reactive treatment to continuous prevention.
Ventilator-associated pneumonia (VAP) remains one of the most significant infection risks in intensive care environments.
Bacterial colonisation and biofilm formation within ventilator circuits can contribute to healthcare-associated infections, increased patient complications and substantial operational burden across critical care settings.
What
- Endotracheal Tube Platform
- Multi-wavelength, High-Intensity (MWHI) antimicrobial Blue Light (aBL)
- Integrated into the Device
How
- Multi-wavelength visible blue light (405–470 nm)
- Disrupts biofilm
- Attacks the problem at the source
Core Value Proposition
- Fewer VAPs
- Fewer antibiotics
- More ICU capacity
- Lower cost per ventilated patient.
Model
- DaaS – Disinfection as a Service
- Recurrent Revenue
- Licensable Technology
Why it matters
- Built‑in
- Always‑on disinfection
- Safe for tissues & material
- Compatible with standard ventilator circuits
The solution and how it works
Lindo Tube embeds patented multi-wavelength antimicrobial blue light technology directly into the endotracheal tube assembly. The system is designed to continuously target pathogens and biofilm formation during mechanical ventilation.
Antimicrobial blue light operates within the visible light spectrum and has been shown to deactivate bacteria and drug-resistant pathogens without harming human tissue.
aBL technology :
- Delivers continuous, autonomous antimicrobial activity
- Targets bacteria at the source
- Non-chemical infection prevention
- Integrates within existing ventilation workflows
Key features and benefits
Lindo Tube is a first-inclass aBL endotracheal tube delivering continuous antimicrobial protection inside the airway, helping reduce ventilator-associated infections without adding complexity to care.
- First-in-class antimicrobial endotracheal tube
- Continuous in-system protection during ventilation
- Uses multi-wavelength, high-intensity aBL technology
- Designed to integrate into existing clinical processes
- Targets biofilm and bacterial contamination
- Non-chemical and non-antibiotic approach
- Designed for ICU and critical care environments
Anesthesiologist & Critical Care Specialist
The LINDO Endotracheal Tube (ETT) offers a novel solution by incorporating germicidal lighting, a technology with the potential to directly reduce microbial load at the point of intubation. This could result in a significant reduction in VAP rates, thereby improving patient outcomes and reducing costs worldwide.”
Addressing ventilator associated pneumonia
VAP generates an economic burden of US$3 billion per year in the United States alone.
Ventilator associated pneumonia remains one of the most serious healthcare associated infections in intensive care units worldwide. Patients requiring mechanical ventilation are particularly vulnerable to bacterial colonisation within the endotracheal tube and ventilator circuit, which can lead to infection, extended ICU stays and increased mortality risk.
Current prevention strategies rely heavily on antibiotics, clinical protocols and manual cleaning processes. The Lindo Tube is being developed to complement existing infection control measures by reducing bacterial burden at the device level.
Ventilator-associated pneumonia accounts for almost 40% of all hospital-acquired pneumonia cases in acute care and remains one of the most lethal complications in critical care settings.
Lindo Tube addresses this challenge head-on. The antimicrobial blue light system operates continuously and automatically — no chemicals, no workflow disruption and no added labour.
It integrates seamlessly into standard endotracheal tube assemblies, targeting microbial biofilm formation with precision.
Made for global health resilience
Developed in collaboration with Mayo Clinic, the world’s leading hospital, the Lindo Tube is designed, engineered, and tested in Australia and built for global deployment.
Our commercialisation strategy is focused from day one on international markets — starting with the United States.
With over 75,000 cases of VAP and an economic burden of US$3 billion per year in the US, preventative solutions that also addresses the rising impact of antimicrobial resistance are needed.
More broadly, antimicrobial resistance now represents a global health security threat that is expected to generate even larger demand for solutions that can reduce pathogen load without driving resistance.
Lindo Tube is positioned to serve both, offering a scalable, clinically integrated solution for ventilated patients while contributing to global efforts to reduce avoidable antibiotic exposure.
We are committed to bring Lindo Tube into frontline healthcare environments. In 2025, Lindo secured $2 million in matched funding through the Australian Government’s Industry Growth Program. This funding supports a $4 million development program to advance the Lindo Tube from Technology Readiness Level 4 to Level 7, enabling preclinical and clinical trials in Australia and the United States.
Proven technology addressing antimicrobial resistance
Powered by patented multi-wavelength, high-intensity aBL (MWHI® aBL), Lindo Tube deactivates pathogens including drug-resistant bacteria and disrupting the formation of biofilm, without harming human tissue or contributing to antimicrobial resistance (AMR).
Bench testing has demonstrated up to 99.9% pathogen reduction in minutes.
Currently designed in collaboration with Mayo Clinic, the Lindo Tube is now advancing to alpha prototype stage before it progresses to real-world clinical trials in ICU conditions. Lindo Tube is supported by strong IP protections, a global regulatory pathway and an expert-led advisory board.
Advanced infection control
To find out more about Lindo Life Science or to enquire about investment opportunities, please get in touch.